An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur/folinic acid (Primary) ; Cisplatin; Oxaliplatin
- Indications Gastric cancer
- Focus Registrational; Therapeutic Use
- Acronyms SOLAR
- Sponsors Taiho Pharmaceutical
- 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
- 02 Aug 2017 Planned End Date changed from 1 May 2018 to 1 May 2019.
- 02 Aug 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2019.